Equities analysts expect American Renal Associates Holdings Inc (NYSE:ARA) to report $204.60 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for American Renal Associates’ earnings. The highest sales estimate is $207.20 million and the lowest is $202.00 million. American Renal Associates posted sales of $187.71 million in the same quarter last year, which suggests a positive year over year growth rate of 9%. The business is scheduled to issue its next quarterly earnings report on Tuesday, November 13th.
According to Zacks, analysts expect that American Renal Associates will report full year sales of $812.00 million for the current fiscal year, with estimates ranging from $804.00 million to $820.00 million. For the next fiscal year, analysts expect that the business will report sales of $883.00 million per share, with estimates ranging from $881.00 million to $885.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover American Renal Associates.
American Renal Associates (NYSE:ARA) last posted its quarterly earnings data on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.17 by $0.03. The firm had revenue of $217.18 million for the quarter, compared to analysts’ expectations of $203.70 million. American Renal Associates had a positive return on equity of 19.60% and a negative net margin of 1.11%.
ARA has been the topic of several recent research reports. ValuEngine upgraded American Renal Associates from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. Goldman Sachs Group initiated coverage on American Renal Associates in a research report on Thursday, July 19th. They set a “neutral” rating and a $16.00 price objective on the stock. Zacks Investment Research cut American Renal Associates from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. Bank of America lowered their price objective on American Renal Associates from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Tuesday, July 10th. Finally, SunTrust Banks restated a “buy” rating and issued a $25.00 price target on shares of American Renal Associates in a research report on Thursday. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. American Renal Associates presently has a consensus rating of “Buy” and an average price target of $19.40.
American Renal Associates traded up $0.19, hitting $21.03, during trading hours on Tuesday, MarketBeat.com reports. 168,028 shares of the stock were exchanged, compared to its average volume of 157,811. The company has a debt-to-equity ratio of 5.30, a current ratio of 1.07 and a quick ratio of 1.10. The stock has a market capitalization of $676.61 million, a price-to-earnings ratio of 30.65, a PEG ratio of 1.34 and a beta of 1.96. American Renal Associates has a 12 month low of $9.91 and a 12 month high of $24.07.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Citadel Advisors LLC increased its position in shares of American Renal Associates by 937.3% in the second quarter. Citadel Advisors LLC now owns 128,282 shares of the company’s stock worth $2,023,000 after purchasing an additional 115,915 shares during the period. Dimensional Fund Advisors LP increased its position in shares of American Renal Associates by 94.3% in the second quarter. Dimensional Fund Advisors LP now owns 495,708 shares of the company’s stock worth $7,818,000 after purchasing an additional 240,542 shares during the period. BlackRock Inc. increased its position in shares of American Renal Associates by 33.2% in the second quarter. BlackRock Inc. now owns 816,103 shares of the company’s stock worth $12,869,000 after purchasing an additional 203,211 shares during the period. Van Berkom & Associates Inc. increased its position in shares of American Renal Associates by 1.4% in the second quarter. Van Berkom & Associates Inc. now owns 2,540,589 shares of the company’s stock worth $40,065,000 after purchasing an additional 34,611 shares during the period. Finally, Spark Investment Management LLC boosted its stake in American Renal Associates by 43.7% in the second quarter. Spark Investment Management LLC now owns 77,000 shares of the company’s stock valued at $1,214,000 after buying an additional 23,400 shares in the last quarter. Institutional investors own 89.39% of the company’s stock.
American Renal Associates Company Profile
American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.
Recommended Story: Stock Symbols Definition, Examples, Lookup
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.